Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VCH-222 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VCH-222 | DRUG | Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37 |
| telaprevir | DRUG | Tablet, Oral, 1125 mg, q12h, Days 18-37 |
Inclusion Criteria: * Healthy males, and/or healthy females of non-childbearing potential, aged 18 to 55 years (inclusive) * Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight \> 50 kg Exclusion Criteria: * Women of child bearing potential * Subjects positive for Hepatitis B, He...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
VCH-222 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its safety and interactions with other medications.
VCH-222 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the drug's potential in treating Hepatitis C.
VCH-222 is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for Hepatitis C.
VCH-222 has one completed Phase 1 clinical trial registered as NCT00958152. This was a drug-drug interaction study of VCH-222 and telaprevir in healthy subjects, conducted in New Zealand with 30 participants. The study was randomized, double-blind, and controlled.
VCH-222 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Hepatitis C. The drug has not completed the clinical trials and regulatory review process required for approval, and its safety and efficacy have not been established.